Ivor (Bemiparin Sodium)

Bemiparin Sodium acts as an anticoagulant in the venous thromboembolism pathway, reducing clot formation in several clinical settings.

• Prevention of venous thromboembolism in surgical patients: lowers the risk of postoperative deep vein thrombosis and pulmonary embolism.
• Treatment of deep vein thrombosis: facilitates clot resolution and prevents extension.
• Prevention of pulmonary embolism: reduces incidence of embolic events in at‑risk individuals.
• Prophylaxis of thromboembolic events in high‑risk medical patients: provides anticoagulation for immobile or critically ill patients.

• Bemiparin Sodium enhances the activity of antithrombin III, which preferentially inhibits activated factor Xa and, to a lesser extent, thrombin (factor IIa). This selective inhibition disrupts the conversion of prothrombin to thrombin and the subsequent formation of fibrin, thereby reducing clot development while preserving some hemostatic function.

Adverse reactions may occur with Bemiparin Sodium use. Patients should be monitored for any signs of bleeding or hypersensitivity.

Common Side Effects

• Injection site pain or erythema: mild discomfort at the administration site.
• Bruising or hematoma: localized bleeding under the skin.
• Nausea or vomiting: gastrointestinal upset.
• Headache: mild to moderate intensity.
• Dizziness: transient light‑headedness.
• Mild bleeding gums: occasional oral bleeding.

Serious or Rare Side Effects

• Heparin‑induced thrombocytopenia (HIT): sudden drop in platelet count.
• Major bleeding: gastrointestinal or intracranial hemorrhage.
• Spinal or epidural hematoma: bleeding in the spinal canal.
• Severe allergic reaction: rash, itching, swelling, or anaphylaxis.
• Elevated liver enzymes: abnormal hepatic function tests.
• Paradoxical thrombosis: new clot formation despite therapy.

Careful assessment and monitoring are essential when using Bemiparin Sodium to minimize risks.

• Renal impairment: adjust therapy and monitor renal function.
• Hepatic impairment: evaluate liver function before initiation.
• Concomitant anticoagulants or antiplatelet agents: increase bleeding risk; use with caution.
• Recent surgery or trauma: assess bleeding risk before administration.
• Pregnancy and breastfeeding: safety not established; weigh benefits against potential risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Bemiparin Sodium may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid)

• Other anticoagulants (e.g., warfarin, direct oral anticoagulants): additive anticoagulant effect.
• Antiplatelet agents (e.g., aspirin, clopidogrel): heightened bleeding risk.
• Thrombolytic therapy (e.g., alteplase): increased hemorrhagic complications.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): potentiates bleeding.
• Spinal or epidural anesthesia: risk of hematoma formation.

Moderate Interactions (Monitor Closely)

• Selective serotonin reuptake inhibitors (SSRIs): may increase bleeding tendency.
• Corticosteroids: potential for gastrointestinal bleeding.
• Renal‑clearing drugs (e.g., aminoglycosides): monitor renal function.
• Herbal supplements with antiplatelet activity (e.g., ginkgo, garlic): observe for signs of bleeding.
• ACE inhibitors: watch for rare synergistic effects on coagulation.